Protocol Ledger

NCT03501979 · Phase II · TERMINATED

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Interventional Phase II clinical trial protocol NCT03501979 sponsored by University of Alabama at Birmingham in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-02-20 Enrollment: 17 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03501979
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)17 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03501979
Protocol FieldVerified Registry Value
NCT IdentifierNCT03501979
Consolidated Lead SponsorUniversity of Alabama at Birmingham
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment17 participants (ACTUAL)
Registered Start Date2019-02-20
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI